CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Moderate Buy” by Brokerages

CG Oncology, Inc. (NASDAQ:CGON) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $69.00.

Several research firms have recently issued reports on CGON. Piper Sandler raised their price objective on CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Truist Financial increased their price target on CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a research note on Monday, January 12th. Royal Bank Of Canada increased their target price on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Finally, Wedbush assumed coverage on shares of CG Oncology in a research note on Thursday, December 11th. They set an “outperform” rating and a $70.00 price target for the company.

CG Oncology Price Performance

CG Oncology stock opened at $58.80 on Friday. CG Oncology has a 1 year low of $14.80 and a 1 year high of $60.00. The firm’s 50 day moving average price is $50.42 and its 200-day moving average price is $42.08. The stock has a market cap of $4.74 billion, a P/E ratio of -28.82 and a beta of 1.32.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The firm had revenue of $2.32 million for the quarter. As a group, equities analysts expect that CG Oncology will post -1.31 EPS for the current year.

Insider Buying and Selling at CG Oncology

In other news, Director James Mulay sold 11,145 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

Several hedge funds have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. purchased a new stake in CG Oncology in the fourth quarter worth about $27,000. Winthrop Capital Management LLC bought a new stake in shares of CG Oncology in the 2nd quarter valued at about $38,000. Strengthening Families & Communities LLC purchased a new stake in shares of CG Oncology in the 3rd quarter worth approximately $40,000. Comerica Bank boosted its stake in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of CG Oncology by 15.2% during the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after purchasing an additional 433 shares in the last quarter. Institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.